banner

Frequently asked Questions

About Doptelet and chronic ITP.1

General Doptelet Information

Doptelet is indicated for the treatment of chronic immune thrombocytopenia in adult patients who have had an insufficient response to a previous treatment.1

Doptelet is a thrombopoietin receptor agonist (TPO-RA) that works with the body to increase platelet production.1

You may see platelet counts rise in as few as 8 days. To read more about the clinical trials and results for Doptelet, visit our efficacy page.1

Patients should store Doptelet tablets in the original package and at room temperature, ie, between 68°F to 77°F (20°C and 25°C). Please remind patients to store Doptelet, and all medicines, out of the reach of children.1

Thrombotic/Thromboembolic Complications: Doptelet has been associated with thrombotic and thromboembolic complications in patients with ITP. In adult patients with chronic immune thrombocytopenia, thromboembolic events (arterial or venous) occurred in 7% (9/128) of patients receiving Doptelet. Consider the potential increased thrombotic risk when administering Doptelet to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions and acquired risk factors. Doptelet should not be administered to patients with ITP in an attempt to normalize platelet counts. Monitor platelet counts and follow the dosing guidelines to achieve target platelet counts. Monitor patients receiving Doptelet for signs and symptoms of thromboembolic events and institute treatment promptly.1

In clinical trials, the most common adverse reactions, which occurred in 10% or more adults living with low platelets in chronic ITP treated with Doptelet, were: headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis. To read more about Doptelet adverse reactions, visit our safety page.1,2

Doptelet can be taken with any kind of food. Please note that food is required when taking Doptelet.1

General ITP information

Immune thrombocytopenia (ITP) is an immune disorder characterized by low platelet counts (<100×109/L). The mechanisms of ITP can involve both increased platelet destruction and impaired platelet production.3

The cause of ITP is not known, but it is due to an immune system error that may be triggered.4

Common symptoms of immune thrombocytopenia include bruising, petechiae, bleeding, and fatigue.5

Doptelet dosing

It is recommended to start all patients with a dosage strength of 20 mg once daily and dose adjustments are based on platelet count response. Assess platelet counts weekly until a stable platelet count greater than or equal to 50×109 /L has been achieved, and then obtain platelet counts monthly thereafter. Do not exceed a daily dose of 40 mg. Please note that 20 mg is the initial dose regimen for all patients except those taking moderate or strong dual inducers or moderate or strong dual inhibitors of CYP2C9 and CYP3A4. Refer to the Titration Calculator or the Full Prescribing Information for more details on titration.1

It is recommended that patients take it as soon as they remember, but they should not take 2 doses at one time to make up for a missed dose. It is advised patients take their next Doptelet dose at their usual scheduled time. Refer to the Full Prescribing Information for more information on Doptelet dosing.1

Doptelet may affect the way other medications work, and other medications may affect the way Doptelet works. Dose adjustments are recommended for adult patients living with low platelets in chronic ITP taking moderate or strong dual CYP2C9 and CYP3A4 inducers or inhibitors. Refer to the Full Prescribing Information to learn more.1

Financial support

Yes, Doptelet Connect provides information about financial assistance programs that may be available for eligible patients, including support for copays and other out-of-pocket costs. To learn more, visit the access page or request support for a Field Reimbursement Manager.

Want more information?

Join the Doptelet email list.

Sign up

  1. DOPTELET (avatrombopag) [prescribing information]. Morrisville, NC: AkaRx, Inc; 2025.
  2. Data on file. Clinical study report for AVA-PED-301. 2025; Sobi, Inc.
  3. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829-2835.
  4. Better Health Channel. Immune thrombocytopenic purpura (ITP). Published August 22, 2022. https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/idiopathic-thrombocytopenic-purpura-itp. Accessed August 6, 2025.
  5. NORD (National Organization for Rare Disorders) website: immune thrombocytopenia. Available at: https://rarediseases.org/rare-diseases/immune-thrombocytopenia/. Accessed August 6, 2025.